Dimethyl fumarate reduces the frequency and function of inflammatory immune cells in relapsing-remitting multiple sclerosis patients

被引：0
|
作者：
Diaz, G. Montes [1 ,2 ,3 ]
Fraussen, J. [1 ,2 ,3 ]
Van Wijmeersch, B. [1 ,2 ,3 ,4 ]
Hupperts, R. [5 ,6 ]
Somers, V. [1 ,2 ,3 ]
机构：
[1] Univ Limburg, Biomed Res Inst, Maastricht, Netherlands
[2] Univ Limburg, Transnat, Maastricht, Netherlands
[3] Hasselt Univ, Sch Life Sci, Diepenbeek, Belgium
[4] Rehabil & MS Ctr, Overpelt, Belgium
[5] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Neurosci, Maastricht, Netherlands
[6] Zuyderland Med Ctr, Acad MS Ctr Limburg, Sittard, Netherlands
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1169
引用
收藏
页码：616 / 617
页数：2
相关论文
共 50 条
  • [41] Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
    Eriksson, Irene
    Cars, Thomas
    Piehl, Fredrik
    Malmstrom, Rickard E.
    Wettermark, Bjorn
    von Euler, Mia
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (02) : 219 - 226
  • [42] Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
    Lundy, Steven K.
    Wu, Qi
    Wang, Qin
    Dowling, Catherine A.
    Taitano, Sophina H.
    Mao, Guangmei
    Mao-Draayer, Yang
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2016, 3 (02):
  • [43] Dimethyl Fumarate: A Review in Relapsing-Remitting MS
    Emma D. Deeks
    Drugs, 2016, 76 : 243 - 254
  • [44] Dimethyl fumarate: A fumaric acid ester under investigation for the treatment of relapsing-remitting multiple sclerosis
    Sobieraj, Diana M.
    Coleman, Craig I.
    FORMULARY, 2012, 47 (11) : 386 - 391
  • [45] NICE approval of dimethyl fumarate could benefit thousands living with relapsing-remitting multiple sclerosis
    Duddy, Martin
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2015, 5 (01) : 7 - 10
  • [46] Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
    Nehzat, Nasim
    Mirmosayyeb, Omid
    Barzegar, Mahdi
    Vosoughi, Reza
    Fazeli, Erfane
    Shaygannejad, Vahid
    NEUROLOGY RESEARCH INTERNATIONAL, 2021, 2021
  • [47] Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
    Irene Eriksson
    Thomas Cars
    Fredrik Piehl
    Rickard E. Malmström
    Björn Wettermark
    Mia von Euler
    European Journal of Clinical Pharmacology, 2018, 74 : 219 - 226
  • [48] Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report
    Harmel, Peter
    Schlunk, Frieder
    Harms, Lutz
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (08) : 1131 - 1133
  • [49] Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
    Carlstrom, Karl E.
    Ewing, Ewoud
    Granqvist, Mathias
    Gyllenberg, Alexandra
    Aeinehband, Shahin
    Enoksson, Sara Lind
    Checa, Antonio
    Badam, Tejaswi V. S.
    Huang, Jesse
    Gomez-Cabrero, David
    Gustafsson, Mika
    Al Nimer, Faiez
    Wheelock, Craig E.
    Kockum, Ingrid
    Olsson, Tomas
    Jagodic, Maja
    Piehl, Fredrik
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [50] COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Mantovani, L. G.
    Furneri, G.
    Cortesi, P. A.
    Puma, E.
    Santoni, L.
    Prosperini, L.
    VALUE IN HEALTH, 2019, 22 : S740 - S741
12345